CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
USA - NYSE:CRL - US1598641074 - Common Stock
167.7 USD
-10.15 (-5.71%)
167.7 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to CRL. CRL was compared to 58 industry peers in the Life Sciences Tools & Services industry. CRL has an average financial health and profitability rating. CRL is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
CRL had positive earnings in the past year.
In the past year CRL had a positive cash flow from operations.
In the past 5 years CRL has always been profitable.
In the past 5 years CRL always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of -0.92%, CRL is doing good in the industry, outperforming 60.34% of the companies in the same industry.
With a Return On Equity value of -2.06%, CRL perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
CRL's Return On Invested Capital of 5.72% is fine compared to the rest of the industry. CRL outperforms 74.14% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CRL is significantly below the industry average of 13.50%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROIC | 5.72% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
1.3 Margins
CRL's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 11.64%, CRL is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
CRL's Operating Margin has been stable in the last couple of years.
With a Gross Margin value of 35.03%, CRL is not doing good in the industry: 62.07% of the companies in the same industry are doing better.
CRL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% |
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CRL is destroying value.
The number of shares outstanding for CRL has been reduced compared to 1 year ago.
CRL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CRL has been reduced compared to a year ago.
2.2 Solvency
CRL has an Altman-Z score of 2.40. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of CRL (2.40) is better than 60.34% of its industry peers.
CRL has a debt to FCF ratio of 4.04. This is a neutral value as CRL would need 4.04 years to pay back of all of its debts.
CRL has a Debt to FCF ratio of 4.04. This is in the better half of the industry: CRL outperforms 70.69% of its industry peers.
CRL has a Debt/Equity ratio of 0.70. This is a neutral value indicating CRL is somewhat dependend on debt financing.
The Debt to Equity ratio of CRL (0.70) is worse than 72.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Altman-Z | 2.4 |
ROIC/WACC0.56
WACC10.22%
2.3 Liquidity
CRL has a Current Ratio of 1.36. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CRL (1.36) is worse than 79.31% of its industry peers.
CRL has a Quick Ratio of 1.10. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
CRL's Quick ratio of 1.10 is on the low side compared to the rest of the industry. CRL is outperformed by 74.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.49% over the past year.
Measured over the past years, CRL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.93% on average per year.
CRL shows a decrease in Revenue. In the last year, the revenue decreased by -1.21%.
CRL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.09% yearly.
EPS 1Y (TTM)4.49%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%11.43%
Revenue 1Y (TTM)-1.21%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%0.59%
3.2 Future
Based on estimates for the next years, CRL will show a small growth in Earnings Per Share. The EPS will grow by 5.95% on average per year.
Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 2.43% on average per year.
EPS Next Y-0.31%
EPS Next 2Y2.66%
EPS Next 3Y4.69%
EPS Next 5Y5.95%
Revenue Next Year-0.98%
Revenue Next 2Y0.71%
Revenue Next 3Y2.15%
Revenue Next 5Y2.43%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CRL is valuated correctly with a Price/Earnings ratio of 15.66.
Compared to the rest of the industry, the Price/Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 93.10% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.13, CRL is valued a bit cheaper.
A Price/Forward Earnings ratio of 15.42 indicates a correct valuation of CRL.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 91.38% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.35. CRL is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.66 | ||
| Fwd PE | 15.42 |
4.2 Price Multiples
96.55% of the companies in the same industry are more expensive than CRL, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 91.38% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.27 | ||
| EV/EBITDA | 12.13 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.75
EPS Next 2Y2.66%
EPS Next 3Y4.69%
5. Dividend
5.1 Amount
No dividends for CRL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
167.7
-10.15 (-5.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners105.46%
Inst Owner Change-2.2%
Ins Owners0.88%
Ins Owner Change6.15%
Market Cap8.25B
Revenue(TTM)4.03B
Net Income(TTM)-69225000
Analysts71.3
Price Target192.74 (14.93%)
Short Float %4.3%
Short Ratio2.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.56%
Min EPS beat(2)11.44%
Max EPS beat(2)23.68%
EPS beat(4)4
Avg EPS beat(4)11.21%
Min EPS beat(4)4.03%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)10.55%
EPS beat(12)12
Avg EPS beat(12)8.62%
EPS beat(16)16
Avg EPS beat(16)6.82%
Revenue beat(2)2
Avg Revenue beat(2)3.59%
Min Revenue beat(2)3.45%
Max Revenue beat(2)3.74%
Revenue beat(4)4
Avg Revenue beat(4)2.63%
Min Revenue beat(4)0.91%
Max Revenue beat(4)3.74%
Revenue beat(8)7
Avg Revenue beat(8)1.68%
Revenue beat(12)10
Avg Revenue beat(12)1.88%
Revenue beat(16)11
Avg Revenue beat(16)1.12%
PT rev (1m)5.84%
PT rev (3m)20.01%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)-1.61%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)6.11%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)3.17%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)2.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.66 | ||
| Fwd PE | 15.42 | ||
| P/S | 2.05 | ||
| P/FCF | 14.27 | ||
| P/OCF | 10.48 | ||
| P/B | 2.46 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.13 |
EPS(TTM)10.71
EY6.39%
EPS(NY)10.88
Fwd EY6.48%
FCF(TTM)11.76
FCFY7.01%
OCF(TTM)16
OCFY9.54%
SpS81.87
BVpS68.14
TBVpS-3.77
PEG (NY)N/A
PEG (5Y)1.75
Graham Number128.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROCE | 7.24% | ||
| ROIC | 5.72% | ||
| ROICexc | 5.88% | ||
| ROICexgc | 13.43% | ||
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% | ||
| FCFM | 14.36% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexgc growth 3Y-14.69%
ROICexgc growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 48.58% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | 4.15 | ||
| Cash Conversion | 87.57% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 2.4 |
F-Score4
WACC10.22%
ROIC/WACC0.56
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)4.49%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%11.43%
EPS Next Y-0.31%
EPS Next 2Y2.66%
EPS Next 3Y4.69%
EPS Next 5Y5.95%
Revenue 1Y (TTM)-1.21%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%0.59%
Revenue Next Year-0.98%
Revenue Next 2Y0.71%
Revenue Next 3Y2.15%
Revenue Next 5Y2.43%
EBIT growth 1Y-25.61%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year34.27%
EBIT Next 3Y14.36%
EBIT Next 5Y10.95%
FCF growth 1Y99.92%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y25.98%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%
CHARLES RIVER LABORATORIES / CRL FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
Can you provide the valuation status for CHARLES RIVER LABORATORIES?
ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
How profitable is CHARLES RIVER LABORATORIES (CRL) stock?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
What is the valuation of CHARLES RIVER LABORATORIES based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CHARLES RIVER LABORATORIES (CRL) is 15.66 and the Price/Book (PB) ratio is 2.46.
How financially healthy is CHARLES RIVER LABORATORIES?
The financial health rating of CHARLES RIVER LABORATORIES (CRL) is 4 / 10.